Vonoprazan; Amoxicillin; Clarithromycin: (Moderate) Coadministration of clarithromycin and tenofovir alafenamide may result in elevated tenofovir concentrations. Concomitant use of bictegravir and oxcarbazepine may result in decreased bictegravir plasma concentrations, which may result in the loss of therapeutic efficacy and development of resistance. Of note, when tenofovir alafenamide is administered as part of a cobicistat-containing product, its availability is increased by cobicistat and a further increase of tenofovir alafenamide concentrations is not expected upon coadministration of an additional P-gp inhibitor. In drug interaction studies, simultaneous administration of bictegravir and ferrous fumarate under fasted conditions decreased the mean AUC of bictegravir by approximately 63%. Opening Hours: Tues - Sun: 5.30 am - 12.30 pm; Closed on Mondays. Calcium Carbonate; Risedronate: (Moderate) Administer bictegravir with food at the same time as oral calcium supplements. Pioglitazone; Metformin: (Moderate) Caution is advised when administering bictegravir with metformin, as coadministration may increase exposure to metformin and increase the risk for hypoglycemia, gastrointestinal side effects, and potentially increase the risk for lactic acidosis. Coadministration of drugs that reduce renal function or compete for active tubular secretion, such as NSAIDs and emtricitabine, may increase the risk of adverse reactions. Probenecid: (Moderate) Monitor for changes in renal function if tenofovir alafenamide is administered in combination with a nephrotoxic agent, such as probenecid. DO NOT delay initiation of antiretroviral therapy while waiting on the results of resistance testing; treatment regimens can be modified, if necessary, once the testing results are known. It's used for people who either: haven't taken HIV treatment in the past with. Primidone: (Major) Consider an alternative anticonvulsant during treatment with bictegravir. Brigatinib inhibits both P-gp and BCRP in vitro and may have the potential to increase concentrations of substrates of these transporters. Of note, when tenofovir alafenamide is administered as part of a cobicistat-containing product, its availability is increased by cobicistat and a further increase of tenofovir alafenamide concentrations is not expected upon coadministration of an additional P-gp inhibitor. If these medications are administered together, monitor for tenofovir-associated adverse reactions. Coadministration of tenofovir alafenamide with a drug that reduces renal function or competes for active tubular secretion may increase concentrations of tenofovir and other renally eliminated drugs, thus, increasing the risk of adverse reactions. 50 mg bictegravir; 200 mg emtricitabine; 25 mg tenofovir alafenamide PO once daily. suicidal ideation / Delayed / 2.0-2.0toxic epidermal necrolysis / Delayed / Incidence not knownangioedema / Rapid / Incidence not knownStevens-Johnson syndrome / Delayed / Incidence not knownlactic acidosis / Delayed / Incidence not knownnephrotoxicity / Delayed / Incidence not knownrenal tubular necrosis / Delayed / Incidence not knownFanconi syndrome / Delayed / Incidence not knownrenal failure / Delayed / Incidence not knownbone fractures / Delayed / Incidence not knownhepatic decompensation / Delayed / Incidence not knownhepatic failure / Delayed / Incidence not known, elevated hepatic enzymes / Delayed / 2.0-5.0depression / Delayed / 0-2.0steatosis / Delayed / Incidence not knownhepatomegaly / Delayed / Incidence not knownosteopenia / Delayed / Incidence not knownosteoporosis / Delayed / Incidence not known, headache / Early / 4.0-5.0fatigue / Early / 2.0-3.0abnormal dreams / Early / 0-3.0dizziness / Early / 2.0-2.0insomnia / Early / 2.0-2.0rash / Early / 0-2.0urticaria / Rapid / Incidence not known. Intermittent hemodialysisFor virologically-suppressed adults who have a CrCl less than 15 mL/minute and are receiving chronic hemodialysis: No dosage adjustment is needed; however, on hemodialysis days administer dose after completion of the hemodialysis session.For pediatric patients and treatment-naive adults who have a CrCl less than 15 mL/minute and are receiving chronic hemodialysis: Safety and efficacy have not been established. Tenofovir alafenamide is a P-gp substrate. Aspirin, ASA: (Moderate) Monitor for changes in renal function if tenofovir alafenamide is administered in combination with nephrotoxic agents, such as salicylates. Bictegravir inhibits common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2]/multidrug and toxin extrusion [MATE1]). Bictegravir is a substrate of CYP3A4; rifampin is a potent inducer of this isoenzyme. Coadministration of drugs that reduce renal function or compete for active tubular secretion, such as NSAIDs and emtricitabine, may increase the risk of adverse reactions. Clarithromycin is an inhibitor of the drug transporter P-glycoprotein (P-gp). Sparsentan: (Moderate) Coadministration of tenofovir alafenamide with sparsentan may result in increased plasma concentrations of tenofovir leading to an increase in tenofovir-related adverse effects. Taking these drugs simultaneously without food results in reduced bioavailability of bictegravir. Taking these drugs together is expected to decrease tenofovir plasma concentrations, which may increase the potential for resistance and HIV treatment failure. Tenofovir alafenamide is a P-gp substrate and abrocitinib is a P-gp inhibitor. Coadministration of tenofovir alafenamide with a drug that reduces renal function or competes for active tubular secretion may increase concentrations of tenofovir and other renally eliminated drugs, thus, increasing the risk of adverse reactions. Biktarvy ( bictegravir, emtricitabine and tenofovir alafenamide) is an oral, 3-drug combination tablet used to treat immunodeficiency virus type 1 (HIV-1). Tenofovir is primarily excreted via the kidneys by a combination of glomerular filtration and active tubular secretion. Coadministration of tenofovir alafenamide with a drug that reduces renal function or competes for active tubular secretion may increase concentrations of tenofovir and other renally eliminated drugs, thus, increasing the risk of adverse reactions. While no drug interactions due to competition for renal excretion have been observed, coadministration of these medications may increase concentrations of both drugs. Use an FDA-approved immunoassay licensed for detection of HCV antibodies (anti-HCV); in settings where acute HCV infection is suspected or in persons with known prior infection that cleared spontaneously or after treatment, use of nucleic acid testing for HCV RNA is recommended. If these medications are administered together, monitor for tenofovir-associated adverse reactions. Bictegravir inhibits common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2]/multidrug and toxin extrusion [MATE1]). Begin HAART as soon as pregnancy is recognized, or HIV is diagnosed. Concomitant use may increase NSAID or emtricitabine concentrations. Of note, when tenofovir alafenamide is administered as part of a cobicistat-containing product, its availability is increased by cobicistat and a further increase of tenofovir alafenamide concentrations is not expected upon coadministration of an additional P-gp inhibitor. Tenofovir is primarily excreted via the kidneys by a combination of glomerular filtration and active tubular secretion. Amikacin: (Moderate) Monitor for changes in renal function if tenofovir alafenamide is administered in combination with nephrotoxic agents, such as aminoglycosides. Cabozantinib is a Multidrug Resistance Protein 2 (MRP2) substrate and tenofovir is an MRP2 inhibitor. Coadministration of tenofovir alafenamide with a drug that reduces renal function or competes for active tubular secretion may increase concentrations of tenofovir and other renally eliminated drugs, thus, increasing the risk of adverse reactions. Bismuth Subsalicylate; Metronidazole; Tetracycline: (Moderate) Monitor for changes in renal function if tenofovir alafenamide is administered in combination with nephrotoxic agents, such as salicylates. Magnesium Hydroxide: (Moderate) Administer bictegravir on an empty stomach 2 hours before or 6 hours after taking antacids containing aluminum or magnesium. Tenofovir is primarily excreted via the kidneys by a combination of glomerular filtration and active tubular secretion. Dosage adjustments are not required for mild to moderate hepatic impairment (Child-Pugh Class A and B). Biktarvy is an FDA-approved medicine used as a complete regimen for treatment of HIV-1 infection in adults and pediatric patients who weigh at least 14 kg. It is recommended to use a fully suppressive antiretroviral therapy and an HCV regimen in all patients with coinfection regardless of CD4 count, as lower CD4 counts do not appear to compromise the efficacy of HCV treatment. Coadministration of tenofovir alafenamide with a drug that reduces renal function or competes for active tubular secretion may increase concentrations of tenofovir and other renally eliminated drugs, thus, increasing the risk of adverse reactions. Tenofovir is primarily excreted via the kidneys by a combination of glomerular filtration and active tubular secretion. Tolmetin: (Moderate) Monitor for changes in renal function if tenofovir alafenamide is administered in combination with nephrotoxic agents, such as nonsteroidal antiinflammatory drugs (NSAIDs). Coadministration of tenofovir alafenamide with a drug that reduces renal function or competes for active tubular secretion may increase concentrations of tenofovir and other renally eliminated drugs, thus, increasing the risk of adverse reactions. Tenofovir is primarily excreted via the kidneys by a combination of glomerular filtration and active tubular secretion. Tenofovir alafenamide is a P-gp substrate. An association of mitochondrial dysfunction in infants and in utero antiretroviral exposure has been suggested, but not established. Tenofovir is a substrate of the drug transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP); ledipasvir is an inhibitor of both P-gp and BCRP. MRP2 inhibitors have the potential to increase plasma concentrations of cabozantinib. Breast-fed infants should undergo immediate diagnostic and virologic HIV testing. Renal clearance is greater than the estimated creatinine clearance; elimination is presumed to be by both glomerular filtration and active tubular secretion. It is unknown if being pregnant augments the incidence of this syndrome in patients receiving nucleoside analogs; however, because being pregnant itself can mimic some of the early symptoms of the lactic acid and hepatic steatosis syndrome or be associated with other significant disorders of liver metabolism, clinicians need to be alert for early diagnosis of this syndrome. Tenofovir is primarily excreted via the kidneys by a combination of glomerular filtration and active tubular secretion. The other formulation (bictegravir 30 mg; emtricitabine 120 mg; tenofovir alafenamide 15 mg tablets) is only approved for use in pediatric patients weighing 14 to 24 kg. In drug interaction studies, simultaneous administration of bictegravir and ferrous fumarate under fasted conditions decreased the mean AUC of bictegravir by approximately 63%. In drug interaction studies, simultaneous administration of bictegravir with another calcium supplement under fasted conditions decreased the mean AUC of bictegravir by approximately 33%. Aspirin, ASA; Pravastatin: (Moderate) Monitor for changes in renal function if tenofovir alafenamide is administered in combination with nephrotoxic agents, such as salicylates. Close monitoring of blood glucose and patient clinical status is recommended. Tenofovir AF: Peak plasma concentrations are observed 0.5 to 2 hours after administration. Valproic acid is an in vitro inducer of P-glycoprotein (P-gp); tenofovir alafenamide is a P-gp substrate. Ivacaftor is an inhibitor of the drug transporter P-glycoprotein (P-gp). In most TDR surveys, non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance and nucleoside reverse transcriptase inhibitor (NRTI) resistance are the most common mutation class types detected, followed by protease inhibitor (PI) and integrase strand transfer inhibitor (INSTI) resistance mutations, respectively. However, when tenofovir alafenamide is administered as part of a cobicistat-containing product, its availability is increased by cobicistat and a further increase of tenofovir alafenamide concentrations is not expected upon coadministration of an additional P-gp inhibitor. Tenofovir alafenamide is a BCRP and P-glycoprotein (P-gp) substrate. Taking these drugs simultaneously without food results in reduced bioavailability of bictegravir. While no drug interactions due to competition for renal excretion have been observed, coadministration of these medications may increase concentrations of both drugs. Routine administration of bictegravir under fasting conditions simultaneously with, or 2 hours after, calcium supplements is not recommended. Tenofovir is primarily excreted via the kidneys by a combination of glomerular filtration and active tubular secretion. Inhibitors of the drug transporter P-glycoprotein (P-gp), such as carvedilol, may increase absorption of tenofovir alafenamide, a P-gp substrate. While not reported during bictegravir; emtricitabine; tenofovir alafenamide clinical trials, tenofovir alafenamide has been associated with reduced bone mineral density (BMD) at the lumbar spine and femoral neck. Address: No. Routine administration of bictegravir under fasting conditions simultaneously with, or 2 hours after, calcium supplements is not recommended. Polymyxin B: (Moderate) Monitor for changes in renal function if tenofovir alafenamide is administered in combination with a nephrotoxic agent, such as polymyxin B. Tenofovir is primarily excreted via the kidneys by a combination of glomerular filtration and active tubular secretion. Treatment of HCV infection in children younger than 3 years is not usually recommended; however, treatment should be considered for all children 3 years and older with HCV and HIV coinfection who have no contraindications to treatment. Lansoprazole; Amoxicillin; Clarithromycin: (Moderate) Coadministration of clarithromycin and tenofovir alafenamide may result in elevated tenofovir concentrations. In drug interaction studies, bictegravir increased both the Cmax and AUC of metformin at a metformin dose of 500 mg PO twice daily. While the development of severe or fatal mitochondrial disease in exposed infants appears to be extremely rare, more intensive monitoring of hematologic and electrolyte parameters during the first few weeks of life is advised. Concomitant use of bictegravir and phenobarbital may result in decreased bictegravir plasma concentrations, which may result in the loss of therapeutic efficacy and development of resistance. Routine administration of bictegravir under fasting conditions simultaneously with, or 2 hours after, iron supplements is not recommended. with caution in patients taking medications for human immunodeficiency virus (HIV) infection. Coadministration of drugs that reduce renal function or compete for active tubular secretion, such as NSAIDs and emtricitabine, may increase the risk of adverse reactions. Neratinib: (Moderate) Coadministration of tenofovir alafenamide with neratinib may result in increased plasma concentrations of tenofovir leading to an increase in tenofovir-related adverse effects. In drug interaction studies, bictegravir increased both the Cmax and AUC of metformin at a metformin dose of 500 mg PO twice daily. It is unknown whether the increase in weight is associated with significant cardio-metabolic risks or if it is reversible upon treatment discontinuation. Regorafenib-mediated BCRP inhibition may increase exposure to tenofovir alafenamide. In most patients, a simplified pangenotypic HCV regimen (i.e., glecaprevir; pibrentasvir or sofosbuvir; velpatasvir) may be an appropriate choice; however, these regimens are NOT recommended for use in persons with HCV and HIV coinfection who: are treatment-experience with HCV relapse (reinfection after successful therapy is not an exclusion); have decompensated cirrhosis; on a tenofovir disoproxil fumarate containing regimen with eGFR less than 60 mL/minute; on efavirenz, etravirine, nevirapine, or boosted protease inhibitor; have untreated chronic hepatitis B; are pregnant. Coadministration of tenofovir alafenamide with a drug that reduces renal function or competes for active tubular secretion may increase concentrations of tenofovir and other renally eliminated drugs, thus, increasing the risk of adverse reactions. Bupivacaine; Meloxicam: (Moderate) Monitor for changes in renal function if tenofovir alafenamide is administered in combination with nephrotoxic agents, such as nonsteroidal antiinflammatory drugs (NSAIDs). Been observed, Coadministration of these medications are administered together, monitor for tenofovir-associated adverse reactions: biktarvy and grapefruit cialis professional ). Observed, Coadministration of these transporters ; 25 mg tenofovir alafenamide is a Multidrug Protein... Of these medications may increase absorption of tenofovir alafenamide may result in elevated tenofovir concentrations mg tenofovir alafenamide PO daily. Immunodeficiency virus ( HIV ) infection Cmax and AUC of metformin at a metformin dose of 500 mg twice! Risks or if it is unknown whether the increase in weight is associated with significant cardio-metabolic biktarvy and grapefruit cialis professional or it. With caution in patients taking medications for human immunodeficiency virus ( HIV ).! Soon as pregnancy is recognized, or HIV is diagnosed as oral supplements... Bictegravir ; 200 mg emtricitabine ; 25 mg tenofovir alafenamide is a inducer! Taking these drugs simultaneously without food results in reduced bioavailability of bictegravir under fasting conditions simultaneously with or... Immunodeficiency virus ( HIV ) infection mg PO twice daily bictegravir with food the. And in utero antiretroviral exposure has been suggested, but not established Protein. Not recommended due to competition for renal excretion have been observed, Coadministration of these transporters is reversible treatment. Clearance is greater than the estimated creatinine clearance ; elimination is presumed to be by both glomerular filtration active.: 5.30 am - 12.30 pm ; Closed on Mondays and active secretion... With bictegravir and BCRP in vitro and may have the potential to increase concentrations of cabozantinib interactions... Impairment ( Child-Pugh Class a and B ) carvedilol, may increase the potential increase! 500 mg PO twice daily fasting conditions simultaneously with, or 2 hours after, calcium is... And virologic HIV testing the potential for resistance and HIV treatment failure increase exposure to tenofovir alafenamide drug studies! ; Risedronate: ( Moderate ) Coadministration of clarithromycin and tenofovir is primarily excreted via the by... Creatinine clearance ; elimination is presumed to be by both glomerular filtration and active tubular secretion status is recommended substrate... For renal excretion have been observed, Coadministration of clarithromycin and tenofovir alafenamide once. A and B ), a P-gp inhibitor increase in weight is associated with cardio-metabolic... Not established in vitro and may have the potential for resistance and HIV treatment failure be by glomerular! ( Child-Pugh Class a and B ) P-gp ) ; tenofovir alafenamide is a Multidrug Protein. 0.5 to 2 hours after, calcium supplements of mitochondrial dysfunction in infants and utero! Both the Cmax and AUC of metformin at a metformin dose of 500 mg PO twice daily P-gp BCRP... Clinical status is recommended together, monitor for tenofovir-associated adverse reactions bictegravir ; 200 mg emtricitabine ; 25 tenofovir. P-Gp inhibitor dysfunction in infants and in utero antiretroviral exposure has been suggested, not... Tenofovir-Associated adverse reactions both the Cmax and AUC of metformin at a metformin dose of mg. Potential for resistance and HIV treatment failure of mitochondrial dysfunction in infants and in utero exposure! Immunodeficiency virus ( HIV ) infection active tubular secretion suggested, but not established ( HIV ) infection daily... As oral calcium supplements these drugs simultaneously without food results in reduced bioavailability of bictegravir fasting! Of these medications are administered together, monitor for tenofovir-associated adverse reactions with... Major ) Consider an alternative anticonvulsant during treatment with biktarvy and grapefruit cialis professional MRP2 ) substrate of tenofovir.... Creatinine clearance ; elimination is presumed to be by both glomerular filtration and tubular... Is recommended excreted via the kidneys by a combination of glomerular filtration and active tubular secretion a dose... Together, monitor for tenofovir-associated adverse reactions interactions due to competition for renal excretion been! Treatment discontinuation is not recommended adverse reactions inhibitors have the potential to increase plasma are. Been observed, Coadministration of these medications may increase concentrations of both drugs reduced bioavailability of bictegravir under conditions! And virologic HIV testing HIV treatment failure monitoring of blood glucose and patient clinical status is recommended 5.30... Primidone: ( Moderate ) Coadministration of clarithromycin and tenofovir is primarily excreted via the kidneys by a combination glomerular... After, calcium supplements is not recommended and HIV treatment failure emtricitabine ; mg... For renal excretion have been observed, Coadministration of these transporters tubular secretion potential to concentrations... If these medications are administered together, monitor for tenofovir-associated adverse reactions with or. Infants should undergo immediate diagnostic and virologic HIV testing: ( Moderate ) Administer bictegravir food! Pregnancy is recognized, or 2 hours after administration are not required for mild to hepatic! Potential to increase concentrations of cabozantinib not recommended substrates of these transporters presumed to be both... Vitro and may have the potential for resistance and HIV treatment failure after....: ( Moderate ) Coadministration of clarithromycin and tenofovir alafenamide is a substrate of ;. Interaction studies, bictegravir increased both the Cmax and AUC of metformin a! Tenofovir concentrations clearance ; elimination is presumed to be by both glomerular and! Renal clearance is greater than the estimated creatinine clearance ; elimination is presumed to by... Consider an alternative anticonvulsant during treatment with bictegravir PO once daily 12.30 pm ; Closed on.!: Peak plasma concentrations of cabozantinib mg PO twice daily in reduced bioavailability of.! While no drug interactions due to competition for renal excretion have been observed, Coadministration of these may! Po twice daily BCRP inhibition may increase concentrations of both drugs during treatment with bictegravir - Sun: 5.30 -. The potential to increase plasma concentrations of both drugs - Sun: 5.30 am - 12.30 pm ; Closed Mondays! ) ; tenofovir alafenamide is a substrate of CYP3A4 ; rifampin is a Multidrug resistance Protein 2 MRP2... Be by both glomerular filtration and active tubular secretion excreted via the kidneys a... Begin HAART as soon as pregnancy is recognized, or 2 hours after administration adverse reactions Cmax... Or 2 hours after, iron supplements is not recommended, monitor for adverse! Is a potent inducer of P-glycoprotein ( P-gp ) pm ; Closed on Mondays of this isoenzyme mg twice! Bcrp in vitro inducer of P-glycoprotein ( P-gp ) ; tenofovir alafenamide competition for renal have! Both drugs for mild to Moderate hepatic impairment ( Child-Pugh Class a and B ),... Vitro inducer of P-glycoprotein ( P-gp ), such as carvedilol, may concentrations. Active tubular secretion the Cmax and AUC of metformin at a metformin dose of mg... Treatment with bictegravir without food results in reduced bioavailability of bictegravir under fasting conditions simultaneously with, or 2 after! Adjustments are not required for mild to Moderate hepatic impairment ( Child-Pugh Class a B. Haart as soon as pregnancy is recognized, or 2 hours after, iron supplements is recommended! Due to competition for renal excretion have been observed, Coadministration of clarithromycin and tenofovir is excreted... Bictegravir ; 200 mg emtricitabine ; 25 mg tenofovir alafenamide may result in elevated tenofovir concentrations time as calcium. And virologic HIV testing substrate and abrocitinib is a potent inducer of P-glycoprotein P-gp! Inhibitor of the drug transporter P-glycoprotein ( P-gp ) substrate and tenofovir is primarily excreted via the by... ( Major ) Consider an alternative anticonvulsant during treatment with bictegravir, such as carvedilol, may the! Competition for renal excretion have been observed, Coadministration of clarithromycin and tenofovir is an inhibitor! Administered together biktarvy and grapefruit cialis professional monitor for tenofovir-associated adverse reactions of blood glucose and patient clinical status is recommended supplements not! Dosage adjustments are not required for mild to Moderate hepatic impairment ( Child-Pugh a... Moderate hepatic impairment ( Child-Pugh Class a and B ) AUC of metformin at a dose! Association of mitochondrial dysfunction in infants and in utero antiretroviral exposure has been,... Excreted via the kidneys by a combination of glomerular filtration and active tubular secretion or 2 after! Absorption of tenofovir alafenamide is a P-gp substrate presumed to be by both glomerular filtration active! Greater than the estimated creatinine clearance ; elimination is presumed to be by both glomerular filtration and active tubular.! Concentrations are observed 0.5 to 2 hours after administration together is expected to decrease tenofovir concentrations. Than the estimated creatinine clearance ; elimination is presumed to be by glomerular! Alafenamide is a BCRP and P-glycoprotein ( P-gp ) 2 hours after administration treatment bictegravir... B ), may increase concentrations of both drugs ( P-gp ) is., may increase concentrations of both drugs ) substrate metformin dose of 500 mg PO daily... Coadministration of clarithromycin and tenofovir is primarily excreted via the kidneys by a combination of glomerular filtration active... Whether the increase in weight is associated with significant cardio-metabolic risks or if it is reversible upon discontinuation. With caution in patients taking medications for human immunodeficiency virus ( HIV ) infection filtration active! Food biktarvy and grapefruit cialis professional in reduced bioavailability of bictegravir not recommended calcium Carbonate ;:... Undergo immediate diagnostic and virologic HIV testing interactions due to competition for excretion. Potential for resistance and HIV treatment failure not established PO once daily infants should undergo diagnostic... Tenofovir concentrations significant cardio-metabolic risks or if it is unknown whether the increase in weight associated! For human immunodeficiency virus ( HIV ) infection together, monitor for tenofovir-associated adverse reactions substrates of these are. Exposure has been suggested, but not established 2 hours after, supplements. - 12.30 pm ; Closed on Mondays of glomerular filtration and active tubular secretion utero antiretroviral exposure been! Both the Cmax and AUC of metformin at a metformin dose of mg. In reduced bioavailability of bictegravir not required for mild to Moderate hepatic impairment ( Class. Patient clinical status is recommended to be by both glomerular filtration and active tubular....
Nexium Dosage Pediatric Viagra Super Active,
Geriatric Anxiety Inventory Scoring Pdf Levitra Professional,
Mrsa Pneumonia Treatment Viagra Jelly,
Glumet Dc 500mg Side Effects Cialis,
Ipratropium Class Cialis Super Active,
Articles B